Navigation Links
Nephros Reports 2011 Fourth Quarter and Full Year Financial Results
Date:3/22/2012

n, FDA approval of our HDF system;
  • products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
  • we may encounter problems with our suppliers and manufacturers;
  • we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
  • HDF therapy may not be accepted in the United States and/or our technology and products may not be accepted in current or future target markets, which could lead to failure to achieve market penetration of our products;
  • we may not be able to sell our ESRD therapy or water filtration products at competitive prices or profitably;
  • we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
  • we may not be able to achieve sales growth in Europe and Canada or expand into other key geographic markets.
  • More detailed information about us and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as amended and our other periodic reports filed with the SEC. We urge investors and security holders to read those documents free of charge at the SEC's web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.


    '/>"/>
    SOURCE Nephros, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
    2. Nephros Reports 2009 Third Quarter Financial Results
    3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
    4. Nephros Signs Development Agreement with STERIS
    5. Nephros Reports 2010 First Quarter Financial Results
    6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
    7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
    8. Nephros Reports 2010 Second Quarter Financial Results
    9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
    10. Nephros Reports 2010 Third Quarter Financial Results
    11. Nephros Rights Offering Registration Statement Declared Effective
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market ... 2014 LeadingAge Annual Meeting in Nashville, TN. ... System, the market leading solution for onsite, remote medication ... term care facilities to safely and securely dispense medication ... to first dose, helps ensure that the correct medication ...
    (Date:10/17/2014)... , Oct. 17, 2014  Ameritox SM , ... the appointment of Thomas Smith , M.D., as ... a field-based team offering scientific resources for healthcare providers, ... has held leadership positions at a variety of healthcare ... benefit both the pain and behavioral health sides of ...
    (Date:10/17/2014)... 2014   DaVita HealthCare Partners Inc. ... nation,s largest and most innovative health care communities, ... the company,s award-winning, leadership development and cultural orientation ... from around the globe were in attendance for ... is a two-day one-of-a-kind experience for new and ...
    Breaking Medicine Technology:Talyst Exhibits at LeadingAge Annual Meeting 2Ameritox Appoints New Chief Medical Officer 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3
    ... Naurex Inc., a clinical-stage company developing innovative ... today announced that it has initiated a Phase II ... Glycine-site Functional Partial Agonist (GFPA) selective modulator of the ... therapy for patients who are not achieving an adequate ...
    ... 2011 Cempra Pharmaceuticals Inc. today announced that ... present at the 2011 Wells Fargo Healthcare Conference at ... Fernandes will provide an overview of the company,s two ... and other infections and TAKSTA™ for the oral treatment ...
    Cached Medicine Technology:Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
    (Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
    (Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
    (Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
    (Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
    (Date:10/19/2014)... Having been working in the garment industry for decades, ... According to James, one of the company’s top designers, many ... high-low skirts that add beauty to them. Chiffon floor length ... unveiled its new selection of 2014 long prom dresses. ... items are available in over 20 popular designs. The company ...
    Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
    ... Rochelle, NY -- The current issue of Medical ... Liebert, Inc., explores how the U.S. military is incorporating ... military personnel serving in the war zones and the ... issue is available online at http://www.liebertpub.com/acu . ...
    ... 4, 2012 As the pharmaceutical industry continues to ... protecting patients from counterfeit medicines, as well as the ... mounted. In an effort to encourage comprehensive public standards ... is proposing a set of recommended best practices that ...
    ... used extensively in Chinese traditional medicine that kill ... the leading causes of tooth loss in children and adults. ... , they say that these substances could have a role ... Stefan Gafner and colleagues explain that the dried root ...
    ... Weight loss surgery is not a cure for type 2 ... a new study published in the British Journal of ... to 80 per cent of diabetes patients have been cured ... that only 41 per cent of patients achieve remission using ...
    ... -- Arrogant people are less likely than humble people to ... Although personal factors (such as previous time commitments and ... how many people are watching) come into play, humility is ... helping hand, according to the study published online Jan. 2 ...
    ... a study that investigates the challenges of disseminating clinical research ... have found that fewer than half of a sample of ... Health (NIH) were published within 30 months of completing the ... issue of the British Medical Journal , which focuses ...
    Cached Medicine News:Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 2Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 3Health News:Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity 4Health News:Scientists reassess weight loss surgery for type 2 diabetes 2Health News:Need Help? Seek Out the Humble 2Health News:Many NIH-funded clinical trials go unpublished over 2 years after completion 2
    Gentamicin is an aminoglycosidic antibiotic that inhibits bacterial growth by inhibiting protein synthesis. Gentamicin is used for prevention and elimination of bacterial contaminants in cell culture...
    LB Agar plates with 10mM Magnesium Sulfate....
    LB Agar plates with 0.1mM EDTA....
    1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
    Medicine Products: